Latest EMD News

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.

Emyria has secured its first Empax clinic in Victoria, marking a significant step in its multi-state expansion and validating its scalable, reimbursed national mental health platform.

Emyria Limited is scaling up its Perth Empax clinic with increased therapist approvals and treatment rooms, setting the stage for broader national clinical growth next year.

Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.

Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.

Emyria has secured a multi-year funding extension with Medibank to launch its Empax mental health programs in Brisbane, marking a key step in its national expansion. This insurer-backed initiative aims to improve access to treatment for complex conditions like treatment-resistant depression and PTSD.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.